Tinninus Assessment Technology

MENODYS announces the addition of 2 new features to its Tinnitus Assessment Technology

Longueuil, Quebec, Canada – MENODYS in collaboration with Pr. Sylvie Hébert of the School of Speech Pathology and Audiology at the University of Montreal announce the addition of new features to its Tinnitus Assessment Technology (TAT), an extension module to assess the Minimum Masking Level and an extension module to assess Residual Inhibition.

“The addition of these 2 new features to the already available Pitch and Loudness features offers a complete all-in-one solution for the objective assessment of tinnitus”, said Richard Côté, Executive Vice President of MENODYS.

“The Tinnitus Assessment Technology offers, to audiology clinicians around the world, a new mean to rapidly and objectively assess tinnitus, prescribe the best tinnitus symptoms attenuation protocol for their patients and finally follow up on the benefits of the symptoms attenuation protocol in reducing the effects of tinnitus over time ”, said Pr. Hébert.

Tinnitus is an important and growing worldwide health issue in audiology affecting more than 30 million Americans and more than 120 million Europeans.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

Sterile saline slush making apparatus

Following the signature of an exclusive worldwide licence agreement, MENODYS announces the 50th successful use of the Sterile Saline Slush Making Apparatus in an organ collection procedure

Longueuil, Quebec, Canada – MENODYS is proud to announce that the Beta prototype of the Sterile Saline Slush Making Apparatus (SSSMA) was used for the 50th time in an operating procedure at the Sacré-Coeur Hospital Organ Collection Center in Montreal, Quebec, Canada. The SSSMA enables the automated production of large volumes of sterile saline slush needed for the preservation of human organs.

Invented by Dr Pierre Marsolais, internal medicine specialist, intensivist and coordinator of the Organ Collection Center of the Sacré-Coeur Hospital of Montreal, this patent pending medical technology, developed jointly with MENODYS, has been designed as a module to automate the transformation of 1 litre bags (up to 9 liters at a time in the Beta prototype) of sterile saline into slush to be used in organ collection and transplant procedures.

“ The fact that the SSSMA Beta prototype has been performing its objective of automating the production of large volume of sterile saline slush to be used in organ collection and transplant procedures for more than 16 months in a real-life setting proves that the technology design and conception is working as planned” said René Gosselin, President of MENODYS. “The benefits of having access to an automated technology for the production of large volumes a sterile saline slush has had a tremendous positive impact on the workload and planning of the Sacré-Coeur Hospital Organ Collection Centre staff” said Dr Pierre Marsolais.

MENODYS is also announcing the signature with Univalor, the Office of Technology Transfer of the University of Montreal, of an exclusive worldwide technology licence agreement on the commercial rights to the SSSMA technology.

About MENODYS

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies. www.menodys.com

About the Sacré-Coeur Organ Collection Centre

The Sacré-Coeur Hospital of Montreal, Quebec, Canada is a supraregional hospital of Montreal affiliated to the university of Montreal. It offers general service care, specialized and ultraspecialized care, a teaching and research environment. Dr Pierre Marsolais founded the Organ Collection Centre in 2013.

About Univalor

Univalor is a technology transfer office. Since 2001, Univalor commercializes the research discoveries and innovations of the researchers of the University of Montreal and its affiliated healthcare centres, Polytechnique Montreal and HEC Montreal. www.univalor.ca